Pancreatic cancer: diagnosis and treatments

详细信息    查看全文

• 作者：Hong-Yu Li (1)
  Zhong-Min Cui (1)
  Jiang Chen (1)
  Xiao-Zhong Guo (1)
  Ying-Yi Li (2)
  
  1. Department of Gastroenterology ; The General Hospital of Shenyang Military Command ; Shenyang ; 110840 ; Liaoning Province ; China
  2. Cancer Research Institute ; Fudan University Shanghai Cancer Center ; Department of Oncology ; Shanghai Medical College ; Fudan University ; Shanghai ; 200032 ; China
  
• 关键词：Pancreatic cancer ; Diagnosis ; Treatment
• 刊名：Tumor Biology
• 出版年：2015
• 出版时间：March 2015
• 年：2015
• 卷：36
• 期：3
• 页码：1375-1384
• 全文大小：220 KB
• 参考文献：1. German, RR, Fink, AK, Heron, M, Stewart, SL, Johnson, CJ (2011) The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol 35: pp. 126-31 CrossRef
  2. Siegel, R, Naishadham, D, Jemal, A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: pp. 11-30 CrossRef
  3. Jones, S, Zhang, X, Parsons, DW, Lin, JC, Leary, RJ (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: pp. 1801-6 CrossRef
  4. Ariyama, J, Suyama, M, Satoh, K, Sai, J (1998) Imaging of small pancreatic ductal adenocarcinoma. Pancreas 16: pp. 396-401 CrossRef
  5. Wasif, N, Bentrem, DJ, Farrell, JJ, Ko, CY, Hines, OJ (2010) Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer 116: pp. 3369-77 CrossRef
  6. Kuvshinoff, BW, Bryer, MP (2000) Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 7: pp. 428-36
  7. Fusari, M, Maurea, S, Imbriaco, M, Mollica, C, Avitabile, G (2010) Comparison between multislice CT and MR imaging in the diagnostic evaluation of patients with pancreatic masses. Radiol Med 115: pp. 453-66 CrossRef
  8. Tempero, MA, Arnoletti, JP, Behrman, S, Ben-Josef, E, Benson, AB (2010) Pancreatic adenocarcinoma. J Natl Compr Canc Netw 8: pp. 972-1017
  9. Wong, JC, Lu, DS (2008) Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol 6: pp. 1301-8 CrossRef
  10. Philip, A, Ramchandani, S, Dorrance, K, Dorrance, C (2008) Sildenafil-induced thrombocytopenia. Ann Intern Med 149: pp. 437-9 CrossRef
  11. Yoshida, T, Matsumoto, T, Sasaki, A, Shibata, K, Aramaki, M (2004) Outcome of paraaortic node-positive pancreatic head and bile duct adenocarcinoma. Am J Surg 187: pp. 736-40 CrossRef
  12. Sahani, DV, Shah, ZK, Catalano, OA, Boland, GW, Brugge, WR (2008) Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 23: pp. 23-33 CrossRef
  13. Lee, JG, Leung, J (1998) Tissue sampling at ERCP in suspected pancreatic cancer. Gastrointest Endosc Clin N Am 8: pp. 221-35
  14. Miyata, H, Kuwahara, K, Sugiyama, S, Iiboshi, T, Serikawa, M (2006) A case of pancreatic solid-pseudopapillary tumor without cystic component in an elderly man. Nihon Shokakibyo Gakkai Zasshi 103: pp. 1288-95
  15. Hanninen, EL, Ricke, J, Amthauer, H, Rottgen, R, Bohmig, M (2005) Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. Acta Radiol 46: pp. 117-25 CrossRef
  16. Park, HS, Lee, JM, Choi, HK, Hong, SH, Han, JK (2009) Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 30: pp. 586-95 CrossRef
  17. Ohtsuka, T, Ideno, N, Aso, T, Nagayoshi, Y, Kono, H (2013) Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci 20: pp. 356-61 CrossRef
  18. Krishna, NB, Mehra, M, Reddy, AV, Agarwal, B (2009) EUS/EUS-FNA for suspected pancreatic cancer: influence of chronic pancreatitis and clinical presentation with or without obstructive jaundice on performance characteristics. Gastrointest Endosc 70: pp. 70-9 CrossRef
  19. Hasan, MK, Hawes, RH (2012) EUS-guided FNA of solid pancreas tumors. Gastrointest Endosc Clin N Am 22: pp. 155-67 CrossRef
  20. Kedia, P, Gaidhane, M, Kahaleh, M (2013) Technical advances in endoscopic ultrasound (EUS)-guided tissue acquisition for pancreatic cancers: how can we get the best results with EUS-guided fine needle aspiration?. Clin Endosc 46: pp. 552-62 CrossRef
  21. Chen, J, Yang, R, Lu, Y, Xia, Y, Zhou, H (2012) Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for solid pancreatic lesion: a systematic review. J Cancer Res Clin Oncol 138: pp. 1433-41 CrossRef
  22. Salehimarzijarani, B, Dadvar, Z, Mousavi, M, Mirsattari, D, Zali, MR (2012) Risk factors for post-ERCP cholangitis in patients with pancreatic cancer from a single referral center in Iran. Asian Pac J Cancer Prev 13: pp. 1539-41 CrossRef
  23. Dibble, EH, Karantanis, D, Mercier, G, Peller, PJ, Kachnic, LA (2012) PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am J Roentgenol 199: pp. 952-67 CrossRef
  24. Strobel, O, Buchler, MW (2013) Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol 10: pp. 203-5 CrossRef
  25. Tempero, MA, Arnoletti, JP, Behrman, SW, Ben-Josef, E, Benson, AB (2012) Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 10: pp. 703-13
  26. Luo, G, Xiao, Z, Long, J, Liu, Z, Liu, L (2013) CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg 17: pp. 2092-8 CrossRef
  27. Bosch, RP, Eijck, CH, Mulder, PG, Jeekel, J (1996) Serum CA19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 43: pp. 710-3
  28. Gui, JC, Yan, WL, Liu, XD (2014) CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis. Clin Exp Med 14: pp. 225-33 CrossRef
  29. Rothlin, MA, Joller, H, Largiader, F (1993) CA 242 is a new tumor marker for pancreatic cancer. Cancer 71: pp. 701-7 CrossRef
  30. Iacobuzio-Donahue, CA, Maitra, A, Shen-Ong, GL, Heek, T, Ashfaq, R (2002) Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol 160: pp. 1239-49 CrossRef
  31. Li, JJ, Li, HY, Gu, F (2014) Diagnostic significance of serum osteopontin level for pancreatic cancer: a meta-analysis. Genet Test Mol Biomarkers 18: pp. 580-6 CrossRef
  32. Bunger, S, Laubert, T, Roblick, UJ, Habermann, JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137: pp. 375-89 CrossRef
  33. Hidalgo, M (2010) Pancreatic cancer. N Engl J Med 362: pp. 1605-17 CrossRef
  34. Kondo, H, Sugano, K, Fukayama, N, Hosokawa, K, Ohkura, H (1997) Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 79: pp. 900-5 CrossRef
  35. Wolfgang, CL, Herman, JM, Laheru, DA, Klein, AP, Erdek, MA (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63: pp. 318-48 CrossRef
  36. Zhang, J, Wang, M, He, S, Liu, Y, Zhang, B (2000) The growth inhibitory effects by transfection of p16 gene on human pancreatic cancer cell line. Zhonghua Wai Ke Za Zhi 38: pp. 457-9
  37. Zhang, L, Gao, J, Li, L, Li, Z, Du, Y (2011) The neuronal pentraxin II gene (NPTX2) inhibit proliferation and invasion of pancreatic cancer cells in vitro. Mol Biol Rep 38: pp. 4903-11 CrossRef
  38. Sato, N, Mizumoto, K, Nagai, E, Tanaka, M (2002) Telomerase as a new target for pancreatic cancer treatment. J Hepatobiliary Pancreat Surg 9: pp. 322-7 CrossRef
  39. Hong, SH, Misek, DE, Wang, H, Puravs, E, Giordano, TJ (2004) An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 64: pp. 5504-10 CrossRef
  40. Guo, J, Wang, W, Liao, P, Lou, W, Ji, Y (2009) Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 100: pp. 2292-301 CrossRef
  41. Qian, JY, Mou, SH, Liu, CB (2012) SELDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of a boosting decision tree model for diagnosis of pancreatic cancer. Asian Pac J Cancer Prev 13: pp. 1911-5 CrossRef
  42. Oettle, H, Neuhaus, P, Hochhaus, A, Hartmann, JT, Gellert, K (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310: pp. 1473-81 CrossRef
  43. Kawarada, Y, Yokoi, H, Isaji, S, Naganuma, T, Tabata, M (1999) Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer. Digestion 60: pp. 120-5 CrossRef
  44. Malleo, G, Marchegiani, G, Salvia, R, Butturini, G, Pederzoli, P (2011) Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. Surg Today 41: pp. 463-70 CrossRef
  45. Evans, DB, Farnell, MB, Lillemoe, KD, Vollmer, C, Strasberg, SM (2009) Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16: pp. 1736-44 CrossRef
  46. Takahashi, H, Ohigashi, H, Ishikawa, O (2012) Pancreaticoduodenectomy for invasive pancreatic cancer (with video). J Hepatobiliary Pancreat Sci 19: pp. 100-8 CrossRef
  47. Srinarmwong, C, Luechakiettisak, P, Prasitvilai, W (2008) Standard whipple鈥檚 operation versus pylorus preserving pancreaticoduodenectomy: a randomized controlled trial study. J Med Assoc Thai 91: pp. 693-8
  48. Takahashi, Y, Kaneoka, Y, Maeda, A, Isogai, M (2011) Distal pancreatectomy with celiac axis resection for carcinoma of the body and tail of the pancreas. World J Surg 35: pp. 2535-42 CrossRef
  49. Strasberg, SM, Linehan, DC, Hawkins, WG (2007) Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg 204: pp. 244-9 CrossRef
  50. Casadei, R, Monari, F, Buscemi, S, Laterza, M, Ricci, C (2010) Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg 62: pp. 41-6 CrossRef
  51. Cunningham, D, Chau, I, Stocken, DD, Valle, JW, Smith, D (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: pp. 5513-8 CrossRef
  52. Hoff, DD, Ervin, T, Arena, FP, Chiorean, EG, Infante, J (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369: pp. 1691-703 CrossRef
  53. Burris, HA, Moore, MJ, Andersen, J, Green, MR, Rothenberg, ML (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: pp. 2403-13
  54. Tempero, M, Plunkett, W, Ruiz Van Haperen, V, Hainsworth, J, Hochster, H (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: pp. 3402-8 CrossRef
  55. Louvet, C, Labianca, R, Hammel, P, Lledo, G, Zampino, MG (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: pp. 3509-16 CrossRef
  56. Heinemann, V, Quietzsch, D, Gieseler, F, Gonnermann, M, Schonekas, H (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: pp. 3946-52 CrossRef
  57. Bernhard, J, Dietrich, D, Scheithauer, W, Gerber, D, Bodoky, G (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial鈥擲AKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26: pp. 3695-701 CrossRef
  58. Moore, MJ, Goldstein, D, Hamm, J, Figer, A, Hecht, JR (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 25: pp. 1960-6 CrossRef
  59. Xiong, HQ, Varadhachary, GR, Blais, JC, Hess, KR, Abbruzzese, JL (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113: pp. 2046-52 CrossRef
  60. Kulke, MH, Blaszkowsky, LS, Ryan, DP, Clark, JW, Meyerhardt, JA (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25: pp. 4787-92 CrossRef
  61. Homma, H, Doi, T, Mezawa, S, Takada, K, Kukitsu, T (2000) A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer 89: pp. 303-13 CrossRef
  62. Liao, WC, Chien, KL, Lin, YL, Wu, MS, Lin, JT (2013) Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 14: pp. 1095-103 CrossRef
  63. Snady, H, Bruckner, H, Cooperman, A, Paradiso, J, Kiefer, L (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89: pp. 314-27 CrossRef
  64. Assifi, MM, Lu, X, Eibl, G, Reber, HA, Li, G (2011) Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 150: pp. 466-73 CrossRef
  65. Spry, N, Harvey, J, Macleod, C, Borg, M, Ngan, SY (2008) 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys 70: pp. 1438-46 CrossRef
  66. Wu, W, Zhu, F, Chang, D, Wang, J, Wang, Y (2013) Dosimetric comparison of treatment plans of pancreatic carcinoma treated with body gamma knife and tomotherapy. Zhongguo Yi Liao Qi Xie Za Zhi 37: pp. 232-4
  67. Guo, XZ, Cui, ZM, Liu, X (2013) Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World J Gastrointest Oncol 5: pp. 20-8
  68. Du, Y, Jin, Z, Meng, H, Zou, D, Chen, J (2013) Long-term effect of gemcitabine-combined endoscopic ultrasonography-guided brachytherapy in pancreatic cancer. J Interv Gastroenterol 3: pp. 18-24 CrossRef
  69. Wang, K, Chen, Z, Meng, Z, Lin, J, Zhou, Z (2011) Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia 27: pp. 101-7 CrossRef
  70. Xie, Q, Jia, L, Liu, YH, Wei, CG (2009) Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo. World J Gastroenterol 15: pp. 737-41 CrossRef
  71. Nicholson, RI, Gee, JM, Harper, ME (2001) EGFR and cancer prognosis. Eur J Cancer 37: pp. S9-15 CrossRef
  72. Strumberg, D, Schultheis, B, Scheulen, ME, Hilger, RA, Krauss, J (2012) Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 30: pp. 1138-43 CrossRef
  73. Zhang, Z, Wang, J, Shen, B, Peng, C, Zheng, M (2012) The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene 491: pp. 194-9 CrossRef
  74. Engelhardt, K, Riley, C, Cooke, L, Mahadevan, D (2006) Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma. Curr Drug Discov Technol 3: pp. 231-43 CrossRef
  75. Takeda, Y, Nakahira, S, Katsura, Y, Kagawa, Y, Okishiro, M (2013) Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer鈥攁 single-institution experience. Gan To Kagaku Ryoho 40: pp. 1884-6
  
• 刊物主题：Cancer Research;
• 出版者：Springer Netherlands
• ISSN：1423-0380

文摘

Pancreatic cancer is one of the deadliest cancers, with exceptionally high mortality. Despite the relatively low incidence rate (10th), it is the fourth leading cause of cancer-related deaths in most developed countries. To improve the early diagnosis of pancreatic cancer and strengthen the standardized comprehensive treatment are still the main focus of pancreatic cancer research. Here, we summarized the rapid developments in the diagnosis and treatments of pancreatic cancer. Regarding diagnosis, we reviewed advances in medical imaging technology, tumor markers, molecular biology (e.g., gene mutation), and proteomics. Moreover, great progress has also been made in the treatments of this disease, including surgical resection, chemotherapy, targeted radiotherapy, targeted minimally invasive treatment, and molecular targeted therapy. Therefore, we also recapitulated the development, advantages, and disadvantages of each of the treatment methods in this review.